News
Research Letter Looks at GLP-1RA Dispensing for Adolescents and Young Adults With Obesity
In a new research letter in JAMA, Mona Sharifi, MD, MPH, and a team of researchers looked at the dispensing of glucagon-like peptide-1 receptor agonists (GLP-1RA) medications to adolescents and young adults (AYAs), aged 12-17 years. GLP-1RA medications have been approved for use in adults with Type 2 diabetes and for adults with obesity for many years, but national attention increased around the FDA approval of semaglutide for weight loss in 2021 for adults and December 2022 for adolescents with obesity.